Commodore Capital LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Commodore Capital LP reported 31 stock positions worth $1.4 billion. Its top holding was Merus (MRUS) at 11.9% of the portfolio, followed by Vaxcyte (PCVX, 9.7%) and Nuvalent Class A (NUVL, 9.3%). Compared with Q3 2024, it opened 4 new positions, sold out of 9, added to 10 and reduced 8. The biggest buy was Nuvalent Class A (NUVL, shares +73%) and the biggest sale an exit from Celldex Therapeutics (CLDX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.4B (Q4 2024)
- SEC Filing
- 0001831942-25-000002 ↗ filed Feb 14, 2025
Holdings Value
Holdings 31 stocks · $1.4B
| MRUS Merus NV | 11.94% | 3,874,182 | $162.9M | Add +15.7% |
| PCVX Vaxcyte Inc. | 9.75% | 1,625,000 | $133.0M | Add +76.6% |
| NUVL Nuvalent Inc. Class A | 9.30% | 1,621,600 | $126.9M | Add +72.5% |
| XENE Xenon Pharmaceuticals Inc. | 7.87% | 2,740,000 | $107.4M | Add +1.5% |
| ELVN Enliven Therapeutics Inc. | 6.93% | 4,205,000 | $94.6M | Add +2.6% |
| VERA Vera Therapeutics Inc. | 6.07% | 1,958,600 | $82.8M | Reduce -20.9% |
| SLNO Soleno Therapeutics Inc. | 5.02% | 1,525,000 | $68.5M | Add +21.0% |
| ALKS Alkermes PLC | 4.85% | 2,300,000 | $66.1M | Reduce -20.7% |
| NRIX Nurix Therapeutics Inc. | 4.14% | 3,000,000 | $56.5M | Add +81.8% |
| COGT Cogent Biosciences Inc. | 3.93% | 6,881,629 | $53.7M | Reduce -8.7% |
| SYRE Spyre Therapeutics Inc. | 3.39% | 1,988,084 | $46.3M | No change |
| VRDN Viridian Therapeutics Inc. | 3.37% | 2,400,000 | $46.0M | Reduce -5.9% |
| SRRK Scholar Rock Holding Corp. | 3.01% | 950,000 | $41.1M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 2.72% | 2,218,425 | $37.2M | Add +64.3% |
| PHVS Pharvaris NV | 2.69% | 1,911,433 | $36.6M | No change |
| MIND MEDICINE MINDMED INC | 2.20% | 4,308,425 | $30.0M | Reduce -46.1% |
| ORKA Oruka Therapeutics Inc. | 2.02% | 1,419,714 | $27.5M | Add +3.6% |
| CRDF Cardiff Oncology Inc. | 1.71% | 5,384,616 | $23.4M | New |
| IKT Inhibikase Therapeutics Inc. | 1.41% | 5,925,000 | $19.3M | New |
| NGNE Neurogene Inc. | 1.34% | 800,000 | $18.3M | Add +300.0% |
| DRUG Bright Minds Biosciences Inc. | 1.32% | 500,000 | $18.0M | New |
| ORIC Oric Pharmaceuticals Inc. | 1.18% | 2,000,000 | $16.1M | No change |
| APGE Apogee Therapeutics Inc. | 0.96% | 290,000 | $13.1M | No change |
| ABVX Abivax SA-ADR | 0.69% | 1,284,110 | $9.4M | No change |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.56% | 750,000 | $7.6M | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.38% | 500,000 | $5.3M | No change |
| CELC Celcuity Inc. | 0.38% | 400,000 | $5.2M | Reduce -73.7% |
| VTGN Vistagen Therapeutics Inc. | 0.34% | 1,575,000 | $4.6M | No change |
| AVTX Avalo Therapeutics Inc. | 0.26% | 483,000 | $3.6M | No change |
| THRD Third Harmonic Bio Inc. | 0.18% | 237,704 | $2.4M | Reduce -82.5% |
| NKTX Nkarta Inc. | 0.06% | 351,848 | $876K | Reduce -92.5% |
Portfolio Sells Q3 2024 → Q4 2024
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −3.44 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −2.79 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −2.20 |
| RYTM Rhythm Pharmaceuticals Inc. | Sold out | 0.00% | −2.13 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −1.85 |
| NKTX Nkarta Inc. | Reduce -92.5% | 0.06% | −1.25 |
| CCCC C4 Therapeutics Inc. | Sold out | 0.00% | −1.21 |
| COGT Cogent Biosciences Inc. | Reduce -8.7% | 3.93% | −1.16 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −1.06 |
| CELC Celcuity Inc. | Reduce -73.7% | 0.38% | −1.03 |
| THRD Third Harmonic Bio Inc. | Reduce -82.5% | 0.18% | −0.97 |
| VERA Vera Therapeutics Inc. | Reduce -20.9% | 6.07% | −0.77 |
| MIND MEDICINE MINDMED INC | Reduce -46.1% | 2.20% | −0.65 |
| TIL Instil Bio Inc. | Sold out | 0.00% | −0.63 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.32 |
| VRDN Viridian Therapeutics Inc. | Reduce -5.9% | 3.37% | −0.25 |
| ALKS Alkermes PLC | Reduce -20.7% | 4.85% | −0.22 |
Portfolio Buys Q3 2024 → Q4 2024
| NUVL Nuvalent Inc. Class A | Add +72.5% | 9.30% | +3.29 |
| PCVX Vaxcyte Inc. | Add +76.6% | 9.75% | +3.18 |
| SRRK Scholar Rock Holding Corp. | New | 3.01% | +3.01 |
| NRIX Nurix Therapeutics Inc. | Add +81.8% | 4.14% | +1.83 |
| CRDF Cardiff Oncology Inc. | New | 1.71% | +1.71 |
| MRUS Merus NV | Add +15.7% | 11.94% | +1.48 |
| IKT Inhibikase Therapeutics Inc. | New | 1.41% | +1.41 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +64.3% | 2.72% | +1.37 |
| DRUG Bright Minds Biosciences Inc. | New | 1.32% | +1.32 |
| XENE Xenon Pharmaceuticals Inc. | Add +1.5% | 7.87% | +1.23 |
| SLNO Soleno Therapeutics Inc. | Add +21.0% | 5.02% | +1.05 |
| NGNE Neurogene Inc. | Add +300.0% | 1.34% | +0.82 |
| ELVN Enliven Therapeutics Inc. | Add +2.6% | 6.93% | +0.39 |
| ORKA Oruka Therapeutics Inc. | Add +3.6% | 2.02% | −0.08 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |